A randomized, prospective, multicenter study of bevacizumab vs. ranibizumab for choroidal neovascularization in myopia

Trial Profile

A randomized, prospective, multicenter study of bevacizumab vs. ranibizumab for choroidal neovascularization in myopia

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Jun 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Ranibizumab (Primary)
  • Indications Choroidal neovascularisation; Myopia
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Jun 2016 New trial record
    • 31 May 2016 Results published in the Pediatric Infectious Disease Journal
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top